Mesoblast Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.00%

Mesoblast Ltd (MSB) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MSB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$-2.00K

≈ $-1.42K USD Cash + Short-term Investments

Total Assets

AU$669.41 Million

≈ $473.65 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2023)

This chart shows how Mesoblast Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MSB asset base.

Liquid Assets Composition Over Time

This chart breaks down Mesoblast Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore MSB long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$-2.00K	-0.0%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$-2.00K	0.00%

Asset Resilience Insights

Limited Liquidity: Mesoblast Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Mesoblast Ltd Industry Peers by Asset Resilience Ratio

Compare Mesoblast Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
89bio Inc NASDAQ:ETNB	Biotechnology	71.60%
Pacific Shuanglin Bio pharmacy Co Ltd SHE:000403	Biotechnology	2.66%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%

Annual Asset Resilience Ratio for Mesoblast Ltd (2013–2023)

The table below shows the annual Asset Resilience Ratio data for Mesoblast Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-06-30	0.00%	AU$-2.00K ≈ $-1.42K	AU$669.41 Million ≈ $473.65 Million	0.00pp
2022-06-30	0.00%	AU$13.00K ≈ $9.20K	AU$662.14 Million ≈ $468.51 Million	+0.01pp
2021-06-30	-0.01%	AU$-49.00K ≈ $-34.67K	AU$744.72 Million ≈ $526.93 Million	-0.01pp
2020-06-30	0.00%	AU$12.00K ≈ $8.49K	AU$733.60 Million ≈ $519.07 Million	0.00pp
2019-06-30	0.00%	AU$21.00K ≈ $14.86K	AU$652.12 Million ≈ $461.41 Million	-0.05pp
2018-06-30	0.06%	AU$392.00K ≈ $277.36K	AU$692.44 Million ≈ $489.95 Million	-5.71pp
2017-06-30	5.76%	AU$37.79 Million ≈ $26.74 Million	AU$655.69 Million ≈ $463.94 Million	+5.40pp
2013-06-30	0.36%	AU$3.19 Million ≈ $2.26 Million	AU$883.71 Million ≈ $625.28 Million	--

pp = percentage points

About Mesoblast Ltd

AU:MSB Australia Biotechnology

Market Cap

$1.94 Billion

AU$2.74 Billion AUD

Market Cap Rank

#6340 Global

#148 in Australia

Share Price

AU$2.11

Change (1 day)

+2.43%

52-Week Range

AU$1.89 - AU$3.07

All Time High

AU$5.21